Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05104801 | Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | unknown | Phase 2 | 37 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00553618 | Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients(DTIC) | unknown | Phase 2 | 160 | University of LouisvilleOTHER | 1 | Oct 29, 2021 |
| clinicaltrials |
| NCT05097378 | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma(PREMIUM) | unknown | Phase 2 | 45 | CCTU- Cancer ThemeOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03925350 | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | unknown | Phase 2 | 41 | California Pacific Medical Center Research InstituteOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04979585 | Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma | unknown | Phase 2 | 66 | Di WuOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04928365 | Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy | unknown | Phase 2 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT04884997 | A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma | unknown | Phase 2 | 90 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03754179 | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma(COMBI-R2) | unknown | Phase 1 / Phase 2 | 63 | Universitair Ziekenhuis BrusselOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | unknown | Phase 1 / Phase 2 | 26 | David Minor, MDOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03313323 | Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma(Zirconipi) | unknown | Phase 2 | 29 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02501551 | Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy | unknown | Phase 2 | 36 | Yonsei UniversityOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01676649 | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | unknown | Phase 2 | 30 | Jewish General HospitalOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT02617849 | Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | unknown | Phase 2 | 30 | Wilson MillerOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04749485 | A Study of HX008 for the Treatment of Patients With Malignant Melanoma | unknown | Phase 2 | 119 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04593485 | Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT03013101 | Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | unknown | Phase 2 | 128 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03269565 | International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma(MIRACULUM) | unknown | Phase 2 | 126 | BiocadINDUSTRY | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04021420 | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma(SONIMEL01) | unknown | Phase 1 / Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04472806 | Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma(MTAM) | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04397770 | Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 21, 2020 | clinicaltrials |
| NCT04200040 | A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients | unknown | Phase 2 | 165 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Feb 27, 2020 | clinicaltrials |
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1(NIBIT-ML1) | unknown | Phase 2 | 184 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03941795 | Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma(BJCH-MM-0624) | unknown | Phase 2 | 99 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04001725 | Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases(OPTIMAL) | unknown | Phase 2 | 110 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01088737 | Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | unknown | Phase 2 / Phase 3 | 60 | Medical University of GrazOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04017897 | The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma | unknown | Phase 2 | 52 | Yonsei UniversityOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03602547 | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | unknown | Phase 2 | 40 | AnewPharmaINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03986515 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03955354 | PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT03917069 | Nab-PCE vs PC for MM After Failure of Anti-PD-1 | unknown | Phase 2 | 145 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03190824 | Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | unknown | Phase 2 | 4 | Syneos HealthOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03818893 | Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | unknown | Phase 2 | 46 | Osaka UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00604136 | Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | unknown | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03454919 | Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Mar 6, 2018 | clinicaltrials |
| NCT03422445 | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03138642 | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT03383237 | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 27, 2017 | clinicaltrials |
| NCT02625337 | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients(IMPemBra) | unknown | Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Sep 15, 2017 | clinicaltrials |
| NCT02023710 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | unknown | Phase 2 | 182 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02452294 | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)(BUMPER) | unknown | Phase 2 | 22 | University Hospital TuebingenOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT03095079 | Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma | unknown | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02962947 | MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | unknown | Phase 2 / Phase 3 | 546 | Azienda Sanitaria di FirenzeOTHER | 0 | Nov 15, 2016 | clinicaltrials |
| NCT02759536 | In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma | unknown | Phase 1 / Phase 2 | 30 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT02202200 | Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma(OPTIMUM) | unknown | Phase 1 / Phase 2 | 40 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT01565837 | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma(SART) | unknown | Phase 2 | 50 | Wolfram SamlowskiOTHER | 1 | Feb 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 4, 2021source: clinicaltrials